Objective-Previous smaller studies have indicated inverse associations between autoantibodies to oxidized low-density lipoprotein epitopes, and cardiovascular disease. The present study investigated associations between autoantibodies against the apolipoprotein B-100 peptides p45 and p210, respectively, and risk of incident cardiovascular disease in a large population-based cohort. Approach and Results-Apolipoprotein B-100 autoantibodies were analyzed by ELISA in a prospective study, including 5393 individuals (aged 46-68 years) belonging to the cardiovascular arm of the Malmö Diet and Cancer study with a follow-up time of >15 years. Subjects that suffered an acute coronary event during follow-up (n=382) had lower levels at baseline of IgM autoantibodies recognizing the native and malondialdehyde-modified apolipoprotein B-100 peptides p45 and p210 and also lower IgG levels recognizing native p210, whereas no association was found with risk for stroke (n=317 
I
mmune responses against modified self-antigens as oxidized low-density lipoprotein (LDL) particles accumulating in the arterial wall are believed to play an important role in the initiation and progression of atherosclerosis. [1] [2] [3] Previous studies have demonstrated presence of T cells responding to oxidized LDL in human lesions, and both plasma and atherosclerotic lesions have been found to contain high levels of autoantibodies recognizing different epitopes in oxidized LDL. [4] [5] [6] [7] [8] Furthermore, animals with genetic deficiencies in the adaptive immune system are characterized by reduced atherosclerotic development during hypercholesterolemic conditions. 2, 9 Oxidized phospholipids and aldehyde-modified peptides of apolipoprotein B-100 (apoB-100) in oxidized LDL are major targets for these immune responses. 2, 10 Both pathogenic and protective immunity has been identified in the atherosclerotic disease process. Experimental animal studies have demonstrated that immunization with oxidized LDL or specific components of oxidized LDL, such as modified phospholipids or apoB-100 peptides, result in atheroprotection. [11] [12] [13] [14] In line with these findings, treatment of mice with human recombinant IgG-specific for an oxidized LDL epitope also reduced the atherosclerotic plaque area in the aorta and decreased plaque inflammation. 15, 16 Particularly, immune responses against the apoB-100 amino acid sequences 661-680 (p45) and 3136-3155 (p210) have been shown to have impact on atherosclerosis. [14] [15] [16] Previous clinical studies measuring autoantibodies to the native and the malondialdehyde (MDA)-modified peptides p45 and p210 have shown inverse associations between autoantibody levels and the severity of arterial disease. [17] [18] [19] [20] [21] [22] [23] Taken together, both the experimental and the clinical studies collectively suggest that activation of adaptive immunity against certain epitopes of apoB-100 is atheroprotective.
To date, most of the clinical studies associating autoantibodies recognizing certain apoB-100 peptides with cardiovascular disease (CVD) have been limited to small selected populations. The present population-based study represents the largest prospective follow-up study analyzing associations between autoantibodies and CVD (in terms of coronary events and stroke) which included 5393 individuals belonging to the cardiovascular arm of the Malmö Diet and Cancer study (MDCS) cohort. 24 We investigated the relationships of plasma levels of IgM and IgG autoantibodies against native p45 (IgMp45 native and IgG-p45 native ), native p210 (IgM-p210 native and IgG-p210 native ), MDA-modified p45 (IgM-p45 MDA and IgGp45 MDA ), and MDA-modified p210 (IgM-p210 MDA and IgGp210 MDA ) and incidence of cardiovascular events. The findings establish that high levels of apoB-100 autoantibodies are associated with a lower incidence of coronary events.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Characteristics of the Study Cohort
In this cohort of 5393 individuals (aged 46-68 years) from the cardiovascular arm of MDCS ( Figure I in the online-only Data Supplement), 398 incident coronary events (66 fatal and 293 nonfatal myocardial infarctions and 39 ischemic heart disease) and 329 incident stroke events (25 fatal and 304 nonfatal strokes, whereof 269 ischemic strokes, 52 hemorrhagic strokes, and 8 unspecified) were registered during follow-up until December 31, 2009 . Baseline characteristics of noncases and CVD cases are shown in Table 1 . In comparison with noncases, those with incident CVD (coronary or stroke events) were older; included more males, more smokers, and hypertensive individuals; and had a higher prevalence of diabetes mellitus. Also blood lipids, hemoglobin A1c, and highsensitive C-reactive protein were increased among CVD cases (Table 1) .
ApoB-100 Autoantibodies and Incident CVD
CVD cases were found to have lower levels of IgM against both native and MDA-modified apoB-100 p45 and p210, respectively, as well as lower levels of IgG against native apoB-100 p210, whereas the other IgG autoantibody levels did not differ between groups (data not shown). When subjects with incident coronary events and incident stroke were analyzed separately, the same pattern of differences was observed between noncases and those with coronary events. However, no association was seen between apoB-100 peptide autoantibodies and risk for total stroke (Table 2) . Also, no association was detected when only individuals with incident ischemic stroke were analyzed (data not shown).
To determine if there were time-dependent associations between autoantibodies and incident coronary events, the autoantibody levels were divided into tertiles that were plotted into All autoantibodies except for IgM-p45 native correlated inversely with LDL levels, whereas only antibodies recognizing p210 showed a significant inverse correlation with apoB (Table 4) .
Discussion
This Swedish prospective population-based study including 5393 white individuals represents the hitherto largest study investigating the role of autoantibodies recognizing apoB-100 peptides in CVD. Several of the previous studies have had retrospective case-control design and included small selected patient populations, such as individuals demonstrating different [17] [18] [19] [20] [21] [22] [23] The present study design, however, made it possible to determine whether the autoantibody levels can predict risk of future cardiovascular events in subjects of the general community. The findings verified that IgG autoantibodies recognizing the native form of p210 are cross-sectionally associated with a lower presence of carotid plaques. Moreover, the IgM-p45 MDA and the IgGp210 native autoantibodies, respectively, demonstrated independent association with lower risk for a future coronary event.
Previous studies analyzing autoantibodies against the whole oxidized LDL particle and their associations with CVD have demonstrated contradictory findings. 25 The inconclusive results may depend on difficulties in the standardization of the antigen. During the oxidation process of the LDL particle, neoepitopes are formed and others degraded. This process may deviate depending on the differences in the composition of the LDL particle isolated from diverse individuals, resulting in a poorly defined antigen. Studies using single LDLderived antigens as phosphorylcholine or apoB-100 peptides have revealed a clearer picture. Previous studies analyzing apoB-100 peptide autoantibodies have demonstrated an inverse association between the autoantibodies and CVD, also in diabetic and systemic lupus erythematosus patients. [17] [18] [19] [20] [21] [22] [23] 26 Thus, the clinical studies suggest a protective role of antibodies recognizing specific antigens in oxidized LDL. This is supported by experimental studies, where treatment of atherosclerosis-prone mice with human recombinant IgG recognizing the MDA-p45 epitope was found to reduce aortic plaque area and plaque inflammation. 15, 16 High plasma levels of IgG-p210 native have previously been associated with less severe coronary lesions, both in nondiabetic and diabetic patients, lower risk of developing myocardial infarction, less severe subclinical atherosclerosis, decreased risk of postoperative cardiovascular death in carotid endarterectomy patients as well as a lower prevalence of CVD in systemic lupus erythematosus patients. 18, 20, 21, 23, 26 We now extend these findings by demonstrating that low levels of IgG-p210 native autoantibodies predict risk of coronary events in a large population-based, prospective study. Interestingly, only antibodies recognizing the p210 epitope, and not the p45 epitope, showed an inverse correlation with apoB. It could be speculated that p210 may be visible for the immune system in the intact LDL particle, whereas the p45 epitope may be hidden in the phospholipid layer and only visible after the oxidation process. Furthermore, it might be that the IgG-p210 native autoantibody recognizes a native or mildly modified p210 peptide and that this epitope plays a more important role in atherogenesis than the more extensively MDA-modified one.
In previous studies, we have detected an inverse association between high levels of autoantibodies recognizing p210 MDA and subclinical atherosclerosis as well as less severe carotid disease in women. 21, 22 In both cases, the epitope was recognized by IgM autoantibodies. An open question is if these represent natural IgM antibodies that have previously been shown to recognize other endogenously generated structures, such as oxidation-specific epitopes, or if they are classical IgM antibodies. T cell-activated B2 cells are known to secrete adaptive IgMs, whereas B1 cells spontaneously secrete natural IgM antibodies. Experimental studies have suggested that B2 cells have a proatherogenic role, whereas B1 cells are atheroprotective depending on their secretion of natural IgM antibodies. [27] [28] [29] Altogether, this may indicate that the IgM antibodies recognizing a modified apoB-100 epitope represent atheroprotective natural IgM antibodies. Interestingly, we have previously demonstrated that subjects with low levels of IgM recognizing methylglyoxal-modified peptide p220 in apoB-100 have an increased risk to develop cardiovascular events and that anti-methylglyoxal-p220 IgM is produced by B1 cells. 30 Another important oxidation-specific epitope on oxidized LDL, the phosphorylcholine epitope, has been found to be recognized by anti-phosphorylcholine IgM that represents an extensively characterized natural IgM antibody. 31, 32 This natural IgM antibody against the phosphorylcholine epitope has been shown to confer protection in experimental atherosclerosis in mice [33] [34] [35] and also to be associated with reduced cardiovascular risk in humans. 36, 37 In support, the present study demonstrated an inverse association between high levels of IgM-p45 MDA and reduced risk of future coronary events. High levels of this IgM antibody have also in a previous study showed an association with a lower prevalence of CVD in systemic lupus erythematosus patients. 26 Furthermore, in patients with type-2 diabetes mellitus, high levels of IgM autoantibodies recognizing AGE-modified apoB-100 were found to be associated with less severe coronary disease. 38 Taken together, both IgM and T cell-dependent IgG antibodies recognizing oxidized LDL epitopes seem to have a protective role in atherogenesis, suggesting important contributions of both innate and adaptive immune responses. The reason why only 2 of the autoantibodies recognizing apoB-100 epitopes measured in the present study were associated with lower risk of incident coronary events has to be further evaluated. One possibility could be that these 2 epitopes appear at different stages of the modification of the LDL particle and become presented in a way that is important for activation of immune responses, reflecting that the extent of LDL oxidation influences the plasma autoantibody levels. In future studies, it will also be of interest to look for associations between the autoantibodies 39, 40 The discrepancies found in the present study that only coronary artery disease and not stroke were associated with apoB-100 autoantibody levels and may reflect the heterogeneous pathogenesis of stroke. Another question still to be answered is why the apoB-100 autoantibodies levels are lower in subjects later suffering a coronary event. Are the antibodies consumed because of a more activated immune system or does the environment with higher levels of different risk factors depress the immune system? It might be that a lower risk factor burden is associated with less atherosclerosis and a more active immune system. On the other hand, a previous study demonstrated significantly higher levels of IgG-p210 native during the first 4 hours after the onset of a myocardial infarction compared with the levels detected after 24 hours and 3 months. 20 This suggests that the induced oxidative stress in the myocardium with a subsequent LDL oxidation can rapidly activate an antibody response in already primed individuals and that these antibodies are consumed directly resulting in baseline levels the day after the event.
One limitation with the present study is that it does not give any information about causality. However, levels of natural IgM antibodies to oxidation-specific epitopes have shown inverse correlation with CVD in several human studies. 31 Their atheroprotective properties may be dependent on the ability to recognize the oxidation-specific epitopes on oxidized LDL. Thus, the IgM-p45 MDA autoantibody may represent a natural IgM antibody explaining its association with lower risk of future coronary events. Another limitation is that antibody levels were only measured at baseline, and no data were available for analyzing changes in antibody levels during follow-up. On the other hand, one of our previous studies showed that levels stayed relatively stable over a 12-month period. 41 In conclusion, the strengths of the present study were the large size of the population and the prospective design together with a 15-year follow-up time, including >600 events, making it unique by allowing for an evaluation if these apoB-100 epitope autoantibodies predict risk for future cardiovascular events. The findings demonstrated an association between high levels of IgM-p45 MDA or IgG-p210 native autoantibodies and a lower risk of coronary events. Taken together, and in the light of previous smaller studies, the present findings establish that high levels of apoB-100 autoantibodies have a protective role in CVD. Analysis of the autoantibody levels may offer an opportunity to identify individuals in need of an immunemodulatory therapy.
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Materials and Methods
Study population
The Malmö Diet and Cancer Study (MDCS) is a prospective population-based cohort (n=28,449) study examining the association between diet and cancer. 1 Subjects born between 1926 and 1945 and living in Malmö were eligible for inclusion in the study. Between October 1991 and February 1994, every other participant was also invited to take part in a sub-study focusing on the epidemiology of carotid artery disease (MDCS cardiovascular cohort, n=6,103). 2 In the present study, plasma samples for assessments of apoB-100 autoantibodies were available in a random subsample of 5,393 subjects participating in the cardiovascular cohort of MDCS (Supplemental figure I) , aged 46 to 68 years old (mean age 57.6). Participants were followed from baseline examination until first event of cardiovascular disease (CVD), emigration from Sweden or death, up until December 31 st , 2009. Ascertainment of cases and validity of the registries used (the Swedish Discharge Registry, the Stroke Register of Malmö and the Cause of Death Registry of Sweden) have been proven to be high. A coronary event was defined as a fatal or non-fatal myocardial infarction, on the basis of the International Classification of Diseases 9th and 10th revisions (ICD-9 and ICD-10) codes 410 and I21, respectively. Death due to ischemic heart disease was defined on the basis of codes 412 and 414 (ICD-9) or I22, I23 and I25 (ICD-10). A stroke event was defined as a fatal-or non-fatal stroke (ICD-9: 430, 431, 434 and 436), hemorrhagic stroke as ICD-9: 430, 431 or ICD-10: I60, I61 and ischemic stroke as ICD-9:434, 436 or ICD-10: I63. Throughout the follow-up period 668 incident first event CVD cases (398 coronary events and 329 strokes, whichever came first) were identified. Within the 398 incident coronary events, 66 fatal myocardial infarctions, 293 non-fatal myocardial infarctions and 39 ischemic heart diseases were identified. Moreover, within the 329 incident stroke events, 25 fatal and 304 non-fatal strokes, whereof 269 ischemic strokes, 52 hemorrhagic strokes and 8 unspecified were recognized. Hypertension was defined as blood pressure ≥140/90 mmHg or blood pressure lowering medication, high cholesterol as >5 mmol/L, smoking as current smoking. Blood pressure, smoking habits and lipid levels were determined as previously described. 2 The study was approved by the Regional Ethical Review Board in Lund (LU 51-90) and was conducted in accordance with the Helsinki Declaration. All subjects gave written consent. The reporting of this cohort study is in accordance with the STROBE guidelines.
B-mode ultrasound
Analysis of the common and bifurcation carotid arteries was performed using an Acuson 128 CT system with a 7-MHz transducer as described previously. 2 Briefly, the right carotid bifurcation was scanned within a predefined window comprising 3 cm of the distal common carotid artery, the bifurcation, and 1 cm of the internal and external carotid arteries. All images for measurement of plaque thickness were obtained in the longitudinal projection showing the thickest intima-media complex. Plaque was defined as a focal thickening of the intima-media exceeding 1.2 mm.
Determination of p45 and p210 autoantibodies
Peptides corresponding to the amino acids from 661 to 680 (p45; IEIGLEGKGFEPTLEALFGK) and amino acids 3136-3155 (p210; KTTKQSFDLSVKAQYKKNKH) of human apoB-100 were synthesized (KJ Ross Petersen AS, Horsholm, Denmark) and used in ELISA. The peptides were modified by 0.5 M MDA for 3 h at 37 °C and dialyzed against PBS containing 1 mM EDTA as described. 3 Native and MDA-modified peptides diluted in PBS pH 7.4 (20 µg/ml) were absorbed to microtiter plate wells (Nunc MaxiSorp, Nunc, Roskilde, Denmark) in an overnight incubation at 4 °C. After washing with PBS containing 0.05% Tween-20 (PBS-T) the coated plates were blocked with SuperBlock in TBS (Thermo Scientific, #37535) for 30 min at room temperature (RT) followed by an incubation of test plasma, diluted 1/100 in TBS containing 0.1% Tween-20 (Thermo Scientific, #28320) and 10% Superblock (TBS-T) for 2h at RT and overnight at 4 °C. After rinsing, deposition of autoantibodies directed to the peptide was detected using biotinylated rabbit polyclonal secondary antibody to human IgG (Abcam ab7159) or IgM antibodies (ICN 67-321, Biomedicals, Inc., Aurora, OH) appropriately diluted in TBS-T. After another incubation for 2h at RT the plates were washed and the bound biotinylated antibodies detected by alkaline phosphatase conjugated streptavidin (BioLegend 405211), incubated for 2h at RT. The colour reaction was developed by using phosphatase substrate kit (Thermo Scientific, #37620) and the absorbance at 405 nm was measured after 90 and 120 min for IgM and IgG, respectively, of incubation at RT. A ratio between the absorbance unit of the individual plasma sample and the absorbance unit of the control plasma (a plasma pool from voluntary healthy blood donors run on each ELISA-plate) was calculated and used for the analysis. Data regarding the specificity and variability of the antibody ELISA have been published previously. 3, 4 In the present study, the intra-assay coefficient of variation was 9-10% for all eight apo-B100 autoantibodies and the inter-assay coefficient 25% for IgM-p45 native and IgM-p45 MDA , 23% for IgGp-45 native and IgGp45 MDA , 13% for IgM-p210 native and IgM-p210 MDA , 22% for IgGp-210 native and IgGp210 MDA , respectively. The intra-assay coefficient of variation was calculated by using the absorbance values of the control plasma pool run on each plate of the same day and the inter-assay by using all the absorbance values of the control plasma pool run during the whole period of analysis.
Statistics
Clinical characteristics are presented as median (interquartile range, IQR) for continuous variables and as percentages for categorical variables. The 182 missing data due to technical reasons in the measurements of apoB-100 autoantibody levels were excluded from analysis (Supplemental figure I) . Skewed continuous variables were logarithmically transformed. An independent sample t test was used to assess normally distributed continuous variables and a Chi-square test for proportions between subjects with and without an incident cardiovascular event. Non-parametric test (Mann-Whitney) was used to assess non-normally distributed continuous variables. Spearman´s correlation coefficient was used to examine the relationship among continuous variables as appropriate. No correction for multiple testing of the eight apo-B100 autoantibodies has been performed. Several of the baseline clinical characteristics that significantly differed between cases and controls (Table 1) were selected as potential confounders: age, sex, triglycerides, LDL, HDL (but not cholesterol, LDL/HDL ratio or apoB), hs-CRP, current smoking, prevalent diabetes mellitus (but not glucose or HbA1c), systolic blood pressure (but not diastolic blood pressure) and blood pressure lowering medication. The confounders not included are represented by related risk factors included in the model. A linear regression model was used to calculate independent associations and logistic regression analyses (with the selected potential confounders included as correction variables) were used to determine associations between apoB-100 autoantibodies and presence of carotid plaques. The Kaplan-Meier method was used to evaluate rates of coronary or stroke event-free survival of apoB-100 autoantibody tertiles, and differences were analyzed by log rank test. Cox proportional hazard regression models were used to compare incidence of coronary or stroke events between autoantibody tertiles and to calculate risk factor adjusted hazard ratios (95% confidence interval, CI). Plots of the hazard function in different groups over time did not indicate that the proportional-hazards assumption was violated.
Supplemental table I.
Hazard ratios (HR) and 95% confidence intervals (CI) for incident coronary event by tertiles of apo-B100 autoantibodies. Associations between tertiles of apoB-100 autoantibodies and incident coronary event was calculated using Cox proportional hazard regression adjusted for age, sex, LDL, HDL, systolic blood pressure, triglycerides, hs-CRP, current smoking, blood pressure lowering medication and prevalent diabetes. Significant associations between number of events and tertiles of autoantibodies were determined with a χ 2 test for linear trend. †
Tertiles of the ratio of the individual plasma sample and the control plasma pool. Significant P-values for trend across tertiles are highlighted in bold text.
